Clinical Trial Detail

NCT ID NCT00184015
Title Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Southern California
Indications

renal cell carcinoma

Therapies

Bevacizumab + Bortezomib

Age Groups: senior adult

No variant requirements are available.